Product Description
Pegilodecakin is an immunotherapy which stimulates the body's natural defenses against cancer and expands tumor-attacking T cells.
Mechanisms of Action: IL10 Inhibitor
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Eli Lilly
Company Location: Eastern America
Company Founding Year: 1876
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Pancreatic Cancer
Phase 2: Non-Small-Cell Lung Cancer
Phase 1: Healthy Volunteers|Renal Cell Carcinoma|Melanoma|Breast Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Ovarian Cancer|Prostate Cancer|Pancreatic Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT03554434 |
Pegilodecakin | N/A |
No longer available |
Colorectal Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Pancreatic Cancer|Melanoma|Renal Cell Carcinoma|Breast Cancer|Ovarian Cancer |
None |
2020-03-12 |
Treatments|Trial Status |
|
NCT02009449 |
IVY | P1 |
Completed |
Ovarian Cancer|Colorectal Cancer|Non-Small-Cell Lung Cancer|Prostate Cancer|Pancreatic Cancer|Breast Cancer|Melanoma|Renal Cell Carcinoma |
2019-02-19 |
2026-07-10 |
||
NCT04194892 |
Willow 3 | P1 |
Completed |
Healthy Volunteers |
2018-03-14 |
2026-07-14 |
Primary Endpoints|Treatments |
|
NCT03381547 |
Willow 2 | P1 |
Completed |
Healthy Volunteers |
2018-02-13 |
2026-07-08 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT03267732 |
Willow 1 | P1 |
Completed |
Healthy Volunteers |
2017-10-17 |
2026-10-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT03382899 |
Cypress 1 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2019-12-06 |
2021-01-20 |
Patient Enrollment|Primary Endpoints|Treatments |
|
NCT03382912 |
Cypress 2 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2019-08-28 |
2020-07-06 |
Primary Endpoints|Study Completion Date|Treatments |
|
2016-003858-33 |
Sequoia, J1L-AM-JZGB | P3 |
Completed |
Pancreatic Cancer |
2020-03-05 |
2022-03-13 |
Treatments |
|
NCT02923921 |
Sequoia | P3 |
Completed |
Pancreatic Cancer |
2019-09-09 |
2020-04-23 |
Patient Enrollment|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/21/2024 |
News Article |
Synthekine Appoints Geoff Nosrati, Ph.D., as Chief Business Officer and Announces Executive Leadership Changes |
|
11/14/2022 |
News Article |
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies |
|
06/11/2021 |
News Article |
World Pancreatic Cancer Clinical Landscape Spotlight 2021-2031 |
|
05/10/2021 |
News Article |
Pancreatic Cancer Therapy Market to Hit 8.1% CAGR to 2025 Driven by Clovis Oncology, Pharmacyte Biotech, Celgene, Amgen |